Study authors	Magnocavallo et al. [17]	Elgendy et al. [18]	Şaylık et al. [19]	Yu et al. [20]	Pan et al. [21]	Zhu et al. [22]
No. of studies included	9	6	10	8	6	3
Year of Publication	2022	2018	2023	2022	2021	2016
Type of studies included	RCTs	RCTs	RCTs	RCTs	RCTs	RCTs
Total No. of patients	2155	775	2187	1693	775	143
No. of patients in CA group	1077	388	NM	834	388	71
No. of patients in MT group	1078	387	NM	859	387	68
Type of ablation strategy	Pulmonary vein isolation (PVI), CFAE Ablation, Posterior Wall Isolation, SVC Isolation, Elimination of AF Triggers, Linear Ablation of the Left Atrial Roof, Cavotricuspid Isthmus and/or Mitral Isthmus	PVI	PVI	PVI, and most of the studies reported additional linear ablation and CFAE Ablation	PVI	PVI
Type of Medical therapy	Medical rhythm and rate control drugs (Amiodarone, class IA, IC, or III)	Rate/rhythm control drugs (+Amiodarone)	Rate/rhythm control drugs	Rate/rhythm control drugs	Rate/rhythm control drugs	Rate control drugs
Follow-up duration (months)	12	26	12	12	16	12
Type of AF	Paroxysmal/Persistent	Paroxysmal/Persistent	Paroxysmal/Persistent	Paroxysmal/Persistent	Paroxysmal/Persistent	Persistent
Primary outcomes	All-cause mortality and HF hospitalization	All-cause mortality	NM	All-cause mortality	All-cause mortality	∆LVEF
Secondary outcomes	CV death, AF recurrence rate, ∆LVEF, ∆MLHFQ, ∆VO2 max, ∆6MWT, and ∆BNP levels	HF hospitalizations, stroke, left ventricular EF improvement, Δ6MWT, ΔMLHFQ	NM	Hospitalization due to HF and the change in LVEF, 6MWT distance, peak VO2, ΔMLHFQ	Hospitalization for HF, remained in AF, change in LVEF, 6-minute walk distance, and MLHFQ.	Changes in cardiac function, exercise capacity, and QOL.